Jørgen Frøkiær

Diagnostik og nye behandlingsmuligheder ved syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

New treatment methods of syndrome of inappropriate
antidiuretic hormone secretion (SIADH) has emerged with the
oral vasopressin V2-receptor antagonist (VV2RA) tolvaptan, but
its therapeutic window remains to be defined. We present the
scientific data and describe treatment possibilities of SIADH
while raising the questions: “Does the present evidence enable
us to identify who to treat with VV2RAs?” and “is VV2RAs
justified as first-line treatment?”.
Original languageDanish
JournalUgeskrift for Laeger
Pages (from-to)1019
Number of pages1,022
Publication statusPublished - 9 Apr 2012

See relations at Aarhus University Citationformats

ID: 50958081